Skip to main content
Equibles

2395 · SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. · Financials

Use 2395 with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research 2395.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
1,239 JPY +10 (+0.81%) At close · Nov 13
Rebalance outlook locked
Market Cap
51.58B JPY
Shares
41.63M
Volume · Nov 13 298.1K Avg daily vol (3M) 301.96K

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →
Revenue
32.52B +0.3%
FY2026 Revenue FY2022–FY2026
Net Income
4.57B -7.3%
FY2026 Net Income FY2022–FY2026
Gross Margin
49.93% -2.4pp
FY2026 Gross Margin FY2022–FY2026
Operating Margin
8.16% -1pp
FY2026 Operating Margin FY2022–FY2026
Operating Cash Flow
8.33B +18.4%
FY2026 Operating Cash Flow FY2022–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item FY2026 FY2025 FY2024 FY2023 FY2022
JPY 32.52B 32.41B 26.45B 25.09B 17.75B
JPY 16.29B 15.45B 12.17B 12.04B 8.06B
JPY 16.24B 16.96B 14.28B 13.05B 9.69B
JPY 2.65B 2.99B 4.16B 5.25B 4.2B
JPY 6.25B 6.01B 6.97B 7.76B 8.18B
JPY 1.71B 1.15B 1.46B 1.71B 1.02B
JPY 4.57B 4.92B 5.53B 6.06B 7.13B
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 9.57B in dividends.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.